EMA Accepts Mylan, Biocon Application For Herceptin Biosimilar
By
The European Medicines Agency (EMA) has accepted a marketing authorization application filed by Mylan for a proposed biosimilar referencing Roche's Herceptin (trastuzumab), for certain HER2-positive breast and gastric cancers. Herceptin,…